From Wikipedia, the free encyclopedia
|Mol. mass||144.1 kDa|
| (what is this?)
2012 results of the EXPEDITION 1 & 2 phase 3 clinical trials were only mildly encouraging. but were said to be the "first evidence that targeting the amyloid cascade can slow the progression of disease.”
- International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ClinicalTrials.gov NCT00749216 Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
- ClinicalTrials.gov NCT00905372 Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)
- "Lilly's Solanezumab Slows Down Alzheimer's Progression". 9 Oct 2012.
- Solanezumab Did it actually work
- "Eli Lilly’s solanezumab faces grim prospects of attaining conditional FDA approval in mild Alzheimer’s". 4 Sep 2012.
- "ALZHEIMER'S DRUG SLOWS MEMORY LOSS BY ONE THIRD". 10 Oct 2012.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|